Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $11.91 USD
Change Today -0.02 / -0.17%
Volume 491.6K
VNDA On Other Exchanges
As of 2:19 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Mihael H. Polymeropoulos M.D.

Founder, Chief Executive Officer, President and Director,Vanda Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 5 board members in 1 different organizations across 1 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. Mihael H. Polymeropoulos, M.D. founded Vanda Pharmaceuticals, Inc. in 2003 and has been its Chief Executive Officer and President since May, 2003. Dr. Polymeropoulos has also been the Chief Financial Officer at Vanda Pharmaceuticals, Inc. since August 6, 2010 and served as its Principal Accounting Officer since August 6, 2010. He served as Vice President and Head of the Pharmacogenetics Department at Novartis Pharmaceuticals Corporation (Maryland). He served as the ...

Read Full Background

Corporate Headquarters*

2200 Pennsylvania Avenue NW
Washington, District Of Columbia 20037

United States

Phone: 202-734-3400
Fax: 202-296-1450

Board Members Memberships*

Founder, Chief Executive Officer, President and Director


Bachelor's Degree
University of Patras

Other Affiliations*

Annual Compensation*

Total Annual Compensation$580,000

Stock Options*

Restricted Stock Awards$613,500
All Other Compensation$18,799
Exercisable Options2,221,398
Exercisable Options Value$14,516,354
Unexercisable Options1,350,250
Unexercisable Options Value$13,573,768
Total Value of Options$28,090,121
Total Number of Options3,571,648

Total Compensation*

Total Annual Cash Compensation$1,033,799
Total Short Term Compensation$580,000
Other Long Term Compensation$632,299
Total Calculated Compensation$2,700,299
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNDA:US $11.94 USD +0.01


Giovanni Caforio M.D.Chief Executive Officer and Director
Bristol-Myers Squibb Company
John C. Lechleiter Ph.D.Chairman, Chief Executive Officer and President
Eli Lilly and Company
Pascal Soriot Chief Executive Officer, Executive Director and Member of Disclosure Committee
AstraZeneca PLC
3.1M GBP
Olivier Brandicourt Chief Executive Officer and Director
Douglas L. Drysdale Chairman, Chief Executive Officer and President
Pernix Therapeutics Holdings, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at